Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274677 · ClinicalTrials.gov registry record · Phase 3
Depression And Bipolar Disorder
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 221
- Enrollment target
NCT00274677 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 221 participants.
The verdict
NCT00274677, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 221 participants
- Enrollment target
Study Summary
This study is an 8-week evaluation of an investigational drug for treating depression in bipolar patients. Depressed patients will be given either an investigational drug or placebo and receive psychiatric assessments of their depression at weekly visits. Study drug and all study-related visits are provided at no cost to the patient. The patient agrees to meet with study research staff for roughly 11 clinic visits.
Interventions
- DRUG Placebo
- DRUG lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274677
The ClinicalTrials.gov registry entry for NCT00274677 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00274677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274677 about?
NCT00274677 is a clinical study titled "Depression And Bipolar Disorder". This study is an 8-week evaluation of an investigational drug for treating depression in bipolar patients. Depressed patients will be given either an investigational drug or placebo and receive psychiatric assessments of their depression at weekly visits. Study drug and all study-related visits are ...
What is the current status of trial NCT00274677?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 221 participants. The study started on 2003-11. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00274677?
The interventions under investigation include: Placebo (DRUG), lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00274677?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.